Physician profile
Asma Khan
NPI 1306009121
$2,518.16
in general payments reported to CMS, 2019-2025
21 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $385 · 2021: $564 · 2022: $611 · 2023: $296 · 2024: $205 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $855.97 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $244.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $206.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $189.08 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $155.42 | 2021-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $146.20 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $132.89 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $81.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.57 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.08 | 2021-2023 | |
| Amarin Pharma, INC. | $75.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.39 | 2025 | |
| Cranial Technologies, INC | $41.90 | 2023-2025 | Doc Band |
| Mylan Specialty L.P. | $37.62 | 2019-2020 | |
| Allergan, INC. | $36.23 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.45 | 2021-2024 | Xifaxan |
| Tandem Diabetes Care, INC. | $20.67 | 2022 | |
| Exact Sciences Corporation | $18.08 | 2025 | Cologuard Collection Kit |
| Athena Bioscience, LLC | $16.67 | 2023 | Qdolo |
| Xeris Pharmaceuticals, INC. | $15.13 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.